-
Pertuzumab, sold
under the
brand name Perjeta, is a
monoclonal antibody used in
combination with
trastuzumab and
docetaxel for the
treatment of metastatic...
-
Pertuzumab/trastuzumab/hyaluronidase, sold
under the
brand name Phesgo, is a fixed-dose
combination medication to
treat adults with HER2-positive breast...
-
pasudotox L01FC01
Daratumumab L01FC02
Isatuximab L01FD01
Trastuzumab L01FD02
Pertuzumab L01FD03
Trastuzumab emtansine L01FD04
Trastuzumab deruxtecan L01FD05 Trastuzumab...
- Mark
Sliwkowski published the
first studies with an
antibody called 2C4 (
pertuzumab or Perjeta),
targeting the Her-2
molecule in
breast and
other cancers...
- NCT01120184 for "A
Study of
Trastuzumab Emtansine (T-DM1) Plus
Pertuzumab/
Pertuzumab Placebo Versus Trastuzumab (Herceptin) Plus a
Taxane in Patients...
- (Herceptin Hylecta), daratumumab/hyaluronidase-fihj (Darzalex Faspro),
pertuzumab/trastuzumab/hyaluronidase–zzxf (Phesgo). In July 2021, the U.S. Food and...
- This is the
first approved therapy for
advanced BCC. 2012:
Perjeta (
pertuzumab): For use in
combination with
Herceptin (trastuzumab) and
docetaxel chemotherapy...
-
Randomization was
stratified by
hormone receptor status,
prior treatment with
pertuzumab, and
history of
visceral disease. The FDA
approved trastuzumab deruxtecan...
-
three w****s for
twelve months.
Adding a
second HER2-targeted antibody,
pertuzumab slightly enhances treatment efficacy. In rare cases,
trastuzumab can disrupt...
-
Zalutumumab ErbB2/HER2 Agonists: Unknown/none Antibodies:
Ertumaxomab Pertuzumab Trastuzumab Trastuzumab deruxtecan Trastuzumab duocarmazine Trastuzumab...
